Pharmaceutical companies have told Brazil's medicines regulator that they see little benefit in approval pathways that use regulatory reliance processes. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
